Prostate Clinic London

What Is Active Surveillance for Prostate Cancer?

If you have been told you have low-risk prostate cancer, you may be wondering why your specialist is suggesting monitoring rather than treatment straight away. Active surveillance is designed for exactly this situation: instead of rushing into surgery or radiotherapy, your cancer is checked closely with PSA tests, MRI scans and, when needed, repeat biopsies.

The aim is to avoid or delay treatment side effects without losing the opportunity for treatment if your cancer changes. You are not “doing nothing” you and your team are following a planned monitoring programme and reviewing your options over time.

What Exactly Is Active Surveillance?

If you choose active surveillance, you remain on a pathway where treatment with curative intent can still be offered if your cancer shows meaningful change. Rather than treating your cancer immediately, your team watches your PSA, MRI and biopsy findings over time to see whether it continues to behave in a lower-risk way.

A good surveillance plan should leave you clear about three things from the start: which tests you will have, how often you will have them and what sort of change would lead to another MRI, biopsy or conversation about treatment.

Who Is Most Likely to Be Suitable for Active Surveillance?

If you have lower-risk localised prostate cancer, you may be suitable for active surveillance. Your doctor will consider your PSA, Grade Group, MRI, biopsy results, cancer stage and how much cancer is present before recommending it.

Your specialist will also talk to you about your age, general health and life expectancy, as well as how you feel about living with a cancer that is being closely monitored rather than treated straight away. NICE recommends active surveillance for CPG 1 disease and includes it as an option for CPG 2; for CPG 3, it may be considered if you do not want immediate radical treatment, while it is not offered for CPG 4-5 disease.

What Do Grade Group and Cancer Volume Have to Do With Surveillance?

If you have Grade Group 1 prostate cancer, active surveillance may be suitable when your other results are favourable. Some Grade Group 2 cancers may also be monitored, but your doctor will consider your PSA, cancer stage, how much cancer was found on biopsy and what your MRI shows.

Your Grade Group is only part of the picture. Your specialist will consider how much cancer was found, what your MRI shows and how your PSA is behaving, then review your biopsy, MRI and PSA together to decide whether surveillance remains appropriate and your cancer still fits a lower-risk pattern.

Evidence Note

BAUS describes active surveillance as being used mainly for low-risk prostate cancer and low-volume intermediate-risk disease. Its UK patient guidance highlights PSA, Gleason score, clinical stage and the amount of cancer found in biopsy samples when considering suitability.

In practical terms, no single result usually determines whether active surveillance is right for you. Your specialist will put your PSA, biopsy, MRI and cancer stage together to build a fuller picture of your individual risk.

Why Would You Choose Surveillance Instead of Treating the Cancer Immediately?

Doctor talking with an older man in a clinic

If you have low-risk prostate cancer, active surveillance can help you avoid or delay the side effects of surgery or radiotherapy. This may help preserve urinary and sexual function while your cancer is monitored closely.

You may never need radical treatment, or active surveillance may allow you to delay surgery or radiotherapy for several years while your cancer remains suitable for monitoring. However, you need regular PSA tests, MRI scans and sometimes biopsies, so you should also consider how comfortable you are with the uncertainty of living with cancer.

Is Active Surveillance the Same as Watchful Waiting?

If you choose active surveillance, you have regular tests so your doctor can offer treatment if your cancer changes. If you are on watchful waiting, your monitoring is usually less intensive and focuses on managing symptoms rather than aiming to cure the cancer.

Active surveillance keeps future treatment options open while your cancer is monitored. With watchful waiting, your doctor is more likely to focus on controlling the cancer if it causes problems.

Active Surveillance vs Watchful Waiting

FeatureActive SurveillanceWatchful Waiting
Main aimMonitor cancer closely while keeping curative treatment available if it progressesMonitor the cancer with less intensive follow-up and use treatment mainly to control the cancer or relieve symptoms if needed
Typical situationLocalised cancer where radical treatment could still be appropriateOften used when age, health or life expectancy make curative treatment less beneficial
PSA testingRegular and structuredUsually less intensive
MRICommonly used as part of surveillanceNot normally used routinely in the same structured way
Repeat biopsyMay be needed depending on PSA, MRI and surveillance protocolUsually not part of routine follow-up
What happens if cancer changes?Further assessment and potentially curative surgery or radiotherapyTreatment generally focuses on controlling symptoms or disease
Overall strategyPart of a potentially curative pathwayUsually a symptom-control/non-curative strategy

What Happens When You First Start Active Surveillance?

If you start active surveillance, your doctor will first make sure your cancer has been assessed accurately. If you have not already had an MRI, NICE recommends that you are offered one when you start active surveillance. If the MRI findings do not agree with your biopsy results, NICE recommends a new MRI-influenced biopsy to reassess the cancer.

This helps confirm that the cancer is suitable for surveillance before regular monitoring begins. Your follow-up plan will depend on how thoroughly your cancer was assessed, including whether you already had an MRI and targeted biopsy.

How Often Is PSA Checked During Active Surveillance?

Your monitoring schedule will be personalised. NICE’s published protocol lists PSA every 3-4 months in year 1 and every 6 months from year 2. Your doctor will focus on the PSA trend rather than one result.

A single PSA rise does not necessarily mean your cancer has progressed. If your PSA pattern becomes concerning, your doctor may arrange an MRI or biopsy to check whether your cancer has changed.

UK Guidance Note

NICE’s published protocol also includes PSA kinetics such as density or velocity, a digital rectal examination at about 12 months and multiparametric MRI at 12-18 months.

From year 2, it lists PSA every 6 months and a digital rectal examination every 12 months, with MRI and/or repeat biopsy if concerns arise. NICE decided in 2025 to update this protocol, so hospitals may use more individualised schedules.

What Role Does MRI Play During Surveillance?

Doctor talking with an older man in a clinic

If you are on active surveillance, MRI helps your doctor monitor known areas of cancer and check whether they look stable or more concerning. Under NICE’s currently published protocol, you may have multiparametric MRI around 12-18 months after starting surveillance. Your own schedule may differ depending on your results and the surveillance protocol used by your clinical team.

MRI is an important monitoring tool, but it does not provide the same tissue information as a biopsy. If your scan suggests progression or your other results become concerning, your doctor may recommend a repeat biopsy before changing your treatment plan.

Will You Need More Prostate Biopsies?

If you are on active surveillance, you may need repeat prostate biopsies, although the timing can vary between surveillance programmes. Your doctor may recommend another biopsy if your PSA, MRI or other findings raise concern about changes in your cancer.

Biopsies help check whether your cancer remains suitable for surveillance. Whether and when you need another one depends on your surveillance programme and other results. If a repeat biopsy shows a higher Grade Group or more cancer, your doctor may discuss treatment options with you.

What Is PSA Density and Why Can It Matter?

If you are on active surveillance, PSA density helps your doctor interpret your PSA level alongside your prostate size. A higher PSA relative to a smaller prostate can be more concerning, but PSA density is not used on its own to make treatment decisions.

This is why your specialist will not look at PSA density in isolation. They will interpret it alongside your PSA trend, MRI and biopsy results. A reassuring PSA density can support the overall picture that your cancer remains suitable for surveillance, but it should not be used on its own to decide whether you need another biopsy or treatment.

Does a Rising PSA Mean You Automatically Need Treatment?

No. If your PSA rises during active surveillance, your doctor may repeat the test first because temporary changes do not always mean your cancer has progressed. If the rise continues, you may need an MRI or repeat biopsy to investigate further.

So, if your PSA rises, that number does not tell the whole story. Your team will look at the pattern over time and may use MRI or biopsy findings to understand whether the cancer has actually changed. If your biopsy shows a higher Grade Group or more cancer, your doctor may discuss treatment; if your other results remain reassuring, surveillance may continue.

What Changes Can Cause Doctors to Recommend Treatment?

Doctor showing an X-ray to an older man

During active surveillance, your specialist looks for changes that may suggest your prostate cancer is becoming more concerning.

  • Higher Grade Group: A repeat biopsy may show that your cancer has become higher grade.
  • More cancer on biopsy: Finding cancer in more tissue samples or a greater amount of cancer may affect whether surveillance remains suitable.
  • Changes on MRI: Progression on MRI can lead to further assessment and sometimes another biopsy.
  • Concerning PSA trend: A persistent change in your PSA pattern may prompt additional tests before treatment is recommended.

Your doctor will consider all your results together, along with your preferences, before deciding whether treatment is needed.

How Safe Is Active Surveillance in the Long Term?

If you have low-risk prostate cancer, active surveillance can offer favourable long-term outcomes while helping you avoid immediate treatment. You will have regular PSA tests, MRI scans and biopsies when needed to monitor your cancer.

The trade-off is important to understand: surveillance can help you avoid or delay the side effects of surgery or radiotherapy, but you need regular follow-up because there remains a risk that the cancer will progress. If your cancer changes, your doctor can discuss treatment with you.

Research Insight

Long-term UK evidence helps explain the trade-off between monitoring and immediate treatment. In the ProtecT trial, 1,643 men with localised prostate cancer were randomised to active monitoring, surgery or radiotherapy and followed for a median of 15 years. Prostate-cancer deaths were uncommon in all groups: 3.1% with active monitoring, 2.2% after prostatectomy and 2.9% after radiotherapy, with no statistically significant difference in prostate-cancer mortality.

However, metastases were more frequent in the active-monitoring group: 9.4% compared with 4.7% after surgery and 5.0% after radiotherapy. This is important when discussing the trade-off between avoiding immediate treatment and accepting a greater risk of progression. Importantly, ProtecT used an older PSA-led ‘active monitoring’ strategy rather than the MRI- and biopsy-informed active-surveillance protocols commonly used today.

Does Everyone on Active Surveillance Eventually Need Treatment?

No. If you are on active surveillance, you may remain on it for many years without needing surgery or radiotherapy. You may need treatment if your cancer changes, further tests show higher-risk disease, or you decide surveillance is no longer right for you.

The aim is not necessarily to avoid treatment forever. It is to avoid treating the cancer before you need to while keeping a close enough watch to identify changes that might make surgery or radiotherapy worth reconsidering.

What Are the Disadvantages of Active Surveillance?

If you are on active surveillance, you may experience anxiety because you know cancer remains in your prostate. You will also need regular PSA tests, appointments, MRI scans and sometimes repeat biopsies, which can be inconvenient.

There is also a possibility that follow-up tests will show that your cancer has progressed or needs to be reclassified. That uncertainty can be difficult for some people, so it is worth considering both the medical and emotional sides of surveillance.

How Do You Decide Whether Active Surveillance Is Right for You?

Doctor talking with an older man in a clinic

If you are considering active surveillance, ask your doctor about your Grade Group, PSA, PSA density, MRI and biopsy results. You should also understand how often you will need PSA tests, MRI scans and repeat biopsies.

It can also help to ask yourself a practical question: would you feel comfortable knowing the cancer is still there as long as your tests continue to suggest it is safe to monitor? Your preferences matter alongside your test results.

Clinical Tip

Before choosing active surveillance, ask your specialist to explain exactly what your team will monitor and what findings would prompt another MRI, biopsy or a discussion about treatment.

Useful questions include which CPG group your cancer falls into, how much Gleason pattern 4 is present if you have Grade Group 2 disease, your PSA density, how much cancer was found on biopsy and whether your MRI and biopsy agree. A clear follow-up plan can make surveillance easier to understand and reduce uncertainty.

Myth vs Fact

MythFact
Active surveillance means doing nothing about the cancer.It is a structured programme of PSA testing, clinical review, imaging and sometimes repeat biopsy.
Only Grade Group 1 cancer can ever be monitored.CPG 2 disease and some Grade Group 2 cancers can be considered for active surveillance.
A rising PSA automatically means you need treatment.PSA changes usually prompt reassessment; treatment decisions are based on the overall evidence.
A stable MRI proves the cancer has not changed.MRI is valuable but cannot exclude every microscopic or histological change.
Everyone on surveillance eventually needs surgery or radiotherapy.Some people remain treatment-free for many years and some never require radical treatment.
Active surveillance and watchful waiting are the same.Active surveillance keeps curative treatment available; watchful waiting usually has a symptom-control strategy.
Choosing surveillance means you cannot change your mind later.You can discuss moving to treatment later because of progression or personal preference.
Surveillance has no risks.It avoids immediate treatment side effects but involves repeated monitoring and some risk of cancer progression.

Key Takeaways

  • Active surveillance is structured monitoring, not leaving prostate cancer untreated.
  • NICE recommends it for appropriate CPG 1 disease.
  • For CPG 2, NICE discusses it alongside surgery and radiotherapy.
  • Selected Grade Group 2 cancers may be monitored; cancer volume, pattern 4, MRI and other risks matter.
  • NICE’s published protocol lists PSA every 3-4 months in year 1 and MRI at 12-18 months.
  • From year 2, the published protocol lists PSA about every 6 months.
  • A single PSA rise does not prove progression.
  • MRI changes usually prompt reassessment and sometimes biopsy, not automatic treatment.
  • Surveillance may delay urinary, sexual or bowel side effects from surgery or radiotherapy.
  • Long-term evidence shows low prostate-cancer mortality in monitored localised disease, although progression remains possible.

Frequently Asked Questions

1. What Is Active Surveillance for Prostate Cancer?
Active surveillance closely monitors suitable localised prostate cancer with PSA tests, MRI and repeat biopsy when needed instead of treating it immediately.

2. Who Is Suitable for Active Surveillance?
Suitability depends on your PSA, Grade Group, MRI, biopsy findings, stage and cancer volume, alongside your age, health, life expectancy and comfort with monitoring.

3. Can Grade Group 2 Prostate Cancer Be Managed With Active Surveillance?
Some Grade Group 2 cancers may be suitable. Your specialist will consider pattern 4, biopsy volume, MRI findings and other risk features.

4. Is Active Surveillance the Same as Watchful Waiting?
No. Active surveillance keeps curative treatment available through regular monitoring; watchful waiting is less intensive and mainly focuses on symptom control.

5. How Often Will You Have PSA Tests During Active Surveillance?
NICE’s published protocol lists PSA every 3-4 months in year 1 and every 6 months from year 2, although your own schedule may differ.

6. How Does MRI Help During Active Surveillance?
MRI helps identify changes that may suggest progression. NICE’s published protocol includes MRI at 12-18 months, with later scans based on your results and local plan.

7. Will You Need Repeat Biopsies During Active Surveillance?
You may. Repeat biopsy can confirm whether surveillance remains suitable, particularly if PSA, MRI or other findings suggest higher-grade or more extensive cancer.

8. Does a Rising PSA Mean You Need Treatment?
Not necessarily. Your doctor may repeat PSA and use MRI or biopsy if a rise persists, because one increase does not prove progression.

9. How Safe Is Active Surveillance in the Long Term?
For suitable low-risk disease, long-term outcomes are favourable, but regular monitoring remains essential so treatment can be reconsidered if the cancer changes.

10. How Do You Decide Whether Active Surveillance Is Right for You?
Discuss your Grade Group, PSA, PSA density, MRI, biopsy results and monitoring schedule, including what would trigger treatment and how you feel about ongoing uncertainty.

Final Thoughts: What Should You Know About Active Surveillance for Prostate Cancer?

Active surveillance can monitor suitable localised prostate cancer while delaying immediate treatment. You and your specialist keep a structured watch using PSA, MRI and biopsy when needed, so important changes can be investigated and treatment reconsidered at the right time.

If you would like specialist advice about whether active surveillance is suitable for you, you can contact Prostate Clinic London to discuss your treatment options and arrange a consultation tailored to your individual needs.

References:

  1. National Institute for Health and Care Excellence (NICE) (2019, updated 2021) Prostate cancer: diagnosis and management. NICE guideline NG131. Available at:
    https://www.nice.org.uk/guidance/ng131
  2. National Institute for Health and Care Excellence (NICE) (2025). May 2025 and August 2025 exceptional surveillance of prostate cancer: diagnosis and management (NICE guideline NG131).
    https://www.nice.org.uk/guidance/ng131/evidence/may-2025-exceptional-surveillance-of-prostate-cancer-diagnosis-and-management-nice-guideline-ng131-15368818141?tab=evidence
  3. British Association of Urological Surgeons (BAUS) (2024) Active surveillance for low to intermediate grade prostate cancer. Available at:
    https://www.baus.org.uk/_userfiles/pages/files/Patients/Leaflets/Active%20surveillance.pdf
  4. NHS (no date) Treatment for prostate cancer. Available at:
    https://www.nhs.uk/conditions/prostate-cancer/treatment/
  5. Hamdy FC, Donovan JL, Lane JA, et al. (2023). Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine, 388, 1547–1558.
    https://www.nejm.org/doi/full/10.1056/NEJMoa2214122
  6. Cambridge University Hospitals NHS Foundation Trust (CUH) (no date) Active surveillance for Cambridge Prognostic Group 1 and 2 (CPG1 and CPG2) early prostate cancer. Available at:
    https://www.cuh.nhs.uk/patient-information/active-surveillance-for-cambridge-prognostic-group-1-and-2-cpg1-and-cpg2-early-prostate-cancer/
  7. Prostate Cancer UK (2026) Active surveillance. Updated May 2026. Available at:
    https://prostatecanceruk.org/prostate-information-and-support/treatments/active-surveillance